Oral Contraceptives, Hormone Replacement Therapy, and Hypertension

Comprehensive Hypertension

Volumn , Issue , 2007, Pages 865-882

  Rosenthal, Talma ^a   Oparil, Suzanne ^b,c  

^a TEL AVIV UNIVERSITY   (Israel)

^b Center for Aging   (United States)

^c University of Alabama at Birmingham and Birmingham Veterans Affairs Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 34547611805     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-03961-1.50073-8     Document Type: Chapter

References (156)

1. JH Laragh, JE Sealey, JGG Ledingham and MA Newton (1967) Oral contraceptives—renin, aldosterone and high blood pressure. JAMA 201 918-922.
2. JW Woods (1967) Oral contraceptives and hypertension. Lancet 2 653-654.
3. IT Lorentz (1962) Parietal lesion and Enavid. BMJ 2 1191.
4. MG Crane, JJ Harris and W Winsor 3rd (1971) Hypertension, oral contraceptive agents, and conjugated estrogens. Ann Intern Med 74 13-21.
5. J Morley Kotchen and TA Kotchen (2003) Impact of female hormones on blood pressure: review of potential mechanisms and clinical studies. Curr Hypertens Rep 5 505-512.
6. MP Stern, BW Brown, WL Haskell, et al. (1976) Cardiovascular risk and use of estrogens or estrogen-progestagen combinations. JAMA 235 811-815.
7. JR Fisch and J Frank (1977) Oral contraceptive and blood pressure. JAMA 237 2499-2503.
8. Royal College of general practitioners' oral contraception study. (1977) Effect on hypertension and benign breast disease of progestogen component in combined oral contraceptives. Lancet 8012 624-626.
9. LD Ostrander, DE Lamphiear, WD Block, et al. (1980) Oral contraceptives and physiological variables. JAMA 244 677-679.
10. IF Godsland, D Crook, M Devenport and V Wynn (1995) Relationship between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Contraception 52 143-149.
11. K Sherif (2000) The effects of hormone replacement therapy and oral contraceptive pills on blood pressure. Prog Cardiovasc Nurs 15 21-23.
12. N Murayama, A Matsunaga, L Tangbanluekal, et al. (2003) Effects of oral contraceptive use on body mass index and blood pressure among female villagers in north-east Thailand. J Biosoc Sci 35 243-261.
13. L Chasan-Taber, WC Willett, JE Manson, et al. (1996) Prospective study of oral contraceptives and hypertension among women in the United States. Circulation 94 483-489.
14. S Siritho, AG Thrift, JJ McNeil, et al. (2003) Melbourne Risk Factor Study (MERFS) Group. Risk of ischemic stroke among users of the oral contraceptive pill: the Melbourne Risk Factor Study (MERFS) Group. Stroke 34 1575-1580.
15. BC Tanis and FR Rosendaal (2003) Venous and arterial thrombosis during oral contraceptive use: risks and risk factors. Semin Vasc Med 3 69-83.
16. G Allais, C De Lorenzo, O Mana and C Benedetto (2004) Oral contraceptives in women with migraine: balancing risks and benefits. Neurol Sci 25 S211-S214.
17. C Seibert, E Barbouche, J Fagan, et al. (2003) Prescribing oral contraceptives for women older than 35 years of age. Ann Intern Med 138 54-64.
18. DB Pettiti (2003) Combination estrogen-progestin oral contraceptives. N Engl J Med 349 1443-1450.
19. American College of Obstetricians and Gynecologists Practice Bulletin. (2006) Use of hormonal contraception in women with coexisting medical conditions: clinical management guidelines for obstetrician-gynecologists. Obstet Gynecol 107 1453-1472.
20. World Health Organization. (2004) Low dose combined oral contraceptives. Improving Access to Quality Care in Family Planning: Medical Eligibility Criteria for Contraceptive Use 3rd ed. Geneva: World Health Organization
21. BG Wren and DA Routledge (1981) Blood pressure changes: oestrogens in climacteric women. Med J Aust 2 528-531.
22. H Lutola (1983) Blood pressure and hemodynamics in postmenopausal women during estradiol-17 beta substitution. Am Clin Res 15(Suppl 38), 1-121.
23. The Writing Group for the PEPI Trial. (1995) Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. JAMA 273 199-208.
24. M Cushman, EN Meilahn, BM Psaty, et al. (1999) Hormone replacement therapy, inflammation, and hemostasis in elderly women. Arterioscler Thromb Vasc Biol 19 893-899.
25. AO Mueck and H Seeger (2004) Effect of hormone therapy on BP in normotensive and hypertensive postmenopausal women. Maturitas 49 189-203.
26. I Karalis, G Beevers, M Beevers and G Lip (2005) Hormone replacement therapy and arterial blood pressure in postmenopausal women with hypertension. Blood Press 14 38-44.
27. A Cagnacci, L Rovati, A Zanni, et al. (1999) Physiological doses of estradiol decrease nocturnal blood pressure in normotensive postmenopausal women. Am J Physiol 276 H1355-H1360.
28. EW Seely, BW Walsh, MD Gerhard and GH Williams (1999) Estradiol with or without progesterone and ambulatory blood pressure in postmenopausal women. Hypertension 33 1190-1194.
29. A. Scuteri, AJG Bos, LJ Brant, et al. (2001) Hormone replacement therapy and longitudinal changes in blood pressure in postmenopausal women. Ann Intern Med 135 229-238.
30. Writing Group for the Women's Health Initiative. (2002) Risk and benefits of estrogen plus progestin in health postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 321-333.
31. The Women's Health Intitiative Steering Committee. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy the Women's Health Initiative Randomized Controlled Trial. JAMA 291 1701-1712.
32. L Mosca, LJ Appel, EJ Benjamin, et al. (2004) Evidence-based guidelines for cardiovascular disease prevention in women. J Am Coll Cardiol 43 900-921.
33. JM Orshal and RA Khalil (2004) Gender, sex hormones, and vascular tone. Am J Physiol Regul Integr Comp Physiol 286 R233-R249.
34. DP Edwards (2005) Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol 67 335-376.
35. DA Schwerz and S Penckofer (2001) Sex differences and the effects of sex hormones on hemostasis and vascular reactivity. Heart Lung 30 401-426.
36. SC Halligan and A Lerman (2005) Hormone replacement therapy and coronary endothelial function in postmenopausal women. Mayo Clin Proc 80 824-828.
37. PA Komesaroff, MD Esler and K Sudhir (1999) Estrogen supplementation attenuates glucocorticoid and catecholamine responses to mental stress in perimenopausal women. J Clin Endocrinol Metab 84 606-610.
38. GG Sofowora, I Singh, HB He, et al. (2005) Effect of acute transdermal estrogen administration on basal, mental stress and cold pressor-induced sympathetic responses in postmenopausal women. Clin Auton Res 15 193-199.
39. H Schunkert, AH Danser, HW Hense, et al. (1997) Effects of estrogen replacement therapy on the renin-angiotensin system in postmenopausal women. Circulation 95 39-45.
40. M Fischer, A Baessler and H Schunkert (2002) Renin angiotensin system and gender differences in cardiovascular system. Cardiovasc Res 53 672-677.
41. J Wilcox, I Hatch, E Gentzshein, et al. (1997) Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. Fertil Steril 67 273-277.
42. AH Karjalainen, H Ruskoaho, Vuolteenaho, et al. (2004) Effects of estrogen replacement therapy on natriuretic peptides and blood pressure. Maturitas 47 201-208.
43. GG Geary, DN Krause and SP Duckles (2000) Estrogen reduces mouse cerebral artery tone through endothelial NOS-and cyclooxygenase-dependent mechanisms. Am J Physiol Heart Circ Physiol 279 H511-H519.
44. MD Kesim, Y Aydin, M Erden and A Atis (2005) Nitric oxide in postmenopausal women taking three different HRT regimens. Maturitas 50 52-57.
45. M Gerhard, BW Walsh, A Tawakol, et al. (1998) Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 98 1158-1163.
46. M Mori, F Tsukahara, T Yoshioka, et al. (2004) Suppression by 17-estradiol of monocyte adhesion to vascular endothelial cells is mediated by estrogen receptors. Life Sci 75 599-609.
47. RE De Meersman, AS Zion, EGV Giardina, et al. (1998) Estrogen replacement, vascular distensibility and blood pressures in postmenopausal women. Am J Physiol 274 H1539-H1544.
48. K Sudhir, MD Elser, GL Jennings and PA Komesaroff (1997) Estrogen supplementation decreases norepinephrine-induced vasoconstriction and total body norepinephrine spillover in perimenopausal women. Hypertension 30 1538-1543.
49. JK Crews and RA Khalil (1999) Gender-specific inhibition of Ca 2+ entry mechanisms of arterial vasoconstriction by sex hormones. Clin Exp Pharmacol Physiol 26 707-715.
50. BH Sung, M Ching, JL Izzo Jr, et al. (1999) Estrogen improves abnormal norepinephrine-induced vasoconstriction in postmenopausal women. J Hypertens 17 523-528.
51. W Vongpatanasin, M Tuncel, Y Mansour, et al. (2001) Transdermal estrogen replacement therapy decreases sympathetic activity in postmenopausal women. Circulation 103 2903-2908.
52. G Weitz, M Elam, J Born, et al. (2001) Postmenopausal estrogen administration suppresses muscle sympathetic nerve activity. Clin Endocrinol Metab 86 344-348.
53. AJ O'Sullivan, LJ Crampton, J Freund, et al. (1998) The route of estrogen replacement confers divergent effects on substrate oxidation and body composition in postmenopausal women. J Clin Invest 102 1035-1040.
54. Z Duanmu, K Lapanowski and JC Dunbar (1997) Insulin-like growth factor-I decreases sympathetic nerve activity: the effect is modulated by glycemic status. Proc Soc Exp Biol Med 216 93-97.
55. U Scherrer, D Randin, L Tappy, et al. (1994) Body fat and sympathetic nerve activity in healthy subjects. Circulation 89 240-263.
56. GF Mitchell, H Parise, EJ Benjamin, et al. (2004) Changes in arterial stiffness and wave reflection with advancing age in healthy men and women: the Framingham Heart Study. Hypertension 43 1239-1245.
57. H Tomiyama, A Yamashina, T Arai, et al. (2003) Influences of age and gender on results of noninvasive brachial-ankle pulse wave velocity measurement—a survey of 12517 subjects. Atherosclerosis 166 303-309.
58. GM London, AP Guerin, B Pannier, et al. (1995) Influences of sex on arterial hemodynamics and blood pressure: role of body height. Hypertension 26 514-519.
59. G Zaydun, H Tomiyama, H Hashimoto, et al. (2006) Menopause is an independent factor augmenting the age-related increase in arterial stiffness in the early postmenopausal phase. Atherosclerosis 184 137-142.
60. C Rajkumar, BA Kingwell, JD Cameron, et al. (1997) Hormonal therapy increases arterial compliance in postmenopausal women. J Am Coll Cardiol 30 350-356.
61. BP McGrath, YL Liang, H Teede, et al. (1988) Age-related deterioration in arterial structure and function in postmenopausal women: impact of hormone replacement therapy. Arterioscler Thromb Vasc Biol 18 1149-1156.
62. K Kawecka, D Czarnecka, A Olszanecka, et al. (2002) The effect of hormone replacement therapy on arterial blood pressure and vascular compliance in postmenopausal women with arterial hypertension. J Hum Hypertens 16 509-516.
63. L Soares da Costa, M Amorin de Oliviera, V Siquiera Martins Rubim, et al. (2004) Effects of hormone replacement therapy or raloxifene on ambulatory blood pressure and arterial stiffness in treated hypertensive postmenopausal women. Am J Cardiol 94 1453-1456.
64. AH Danser, FH Derkx, MA Schalekamp, et al. (1998) Determinants of interindividual variation of renin and prorenin concentrations: evidence for a sexual dimorphism of (pro)renin levels in humans. J Hypertens 16 853-862.
65. AJ Proudler, AL Ahmed, D Crook, et al. (1995) Hormone replacement therapy and serum angiotensin-converting enzyme activity in postmenopausal women. Lancet 346 89-90.
66. KB Brosnihan, D Weddle, MS Anthony, et al. (1997) Effects of chronic hormone replacement on the renin-angiotensin system in cynomolgus monkeys. J Hypertens 15 719-726.
67. SA Dean, J Tan, O'Brien and FH Leenen (2005) 17|3-estradiol downregulates tissue angiotensin-converting enzyme and ANG II type 1 receptor in female rats. Am J Regul Integr Comp Physiol 288 R759-R766.
68. KB Brosnihan, P Li, D Ganten and CM Ferrario (1997) Estrogen protects transgenic hypertensive rats by shifting the vasoconstrictor-vasodilator balance of RAS. Am J Integr Comp Physiol 273 R1908-R1915.
69. G Nickenig, AT Baumer, C Crohe, et al. (1998) Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation 97 2197-2201.
70. DM Roesch, Y Tian, W Zheng, et al. (2000) Estradiol attenuates angiotensin-induced aldosterone secretion in ovariectomized rats. Endocrinology 141 4629-4636.
71. Z Wu, C Maric, DM Roesch, et al. (2003) Estrogen regulates adrenal angiotensin AT1 receptors by modulating AT1 receptor translation. Endocrinology 144 3251-3261.
72. C Klett, D Ganten, W Hellman, et al. (2002) Regulation of angiotensinogen synthesis and secretion by steroid hormones. Endocrinology 130 3660-3668.
73. M Feldmer, M Laking, S Takahashi, et al. (1991) Glucocorticoid- and estrogen-responsive elements in the 5'-flanking region of the rat angiotensinogen gene. J Hypertens 9 1005-1012.
74. J Myers and T Morgan (1983) The effect of sodium intake on the blood pressure related to age and sex. Clin Exp Hypertens A 5 99-118.
75. T Tominaga, H Suzuki, Y Ogata, et al. (1991) The role of sex hormones and sodium intake in postmenopausal hypertension. J Hum Hypertens 5 495-500.
76. Y Yamori, L Liu, K Ikeda, et al. (2001) Different associations of blood pressure with 24-hr urinary sodium excretion among pre- and post-menopausal women. WHO Cardiovascular Diseases and Alimentary Comparison (WHO-CARDIAC) Study. J Hypertens 19 535-538.
77. A Pechere-Bertschi and M Burnier (2004) Female sex hormones, salt, and blood pressure regulation. Am J Hypertens 17 994-1001.
78. IH Schulman, P Aranda, L Raij, et al. (2006) Surgical menopause increases salt sensitivity of blood pressure. Hypertension 47 1168-1174.
79. VM Miller and PM Vanhoutte (1991) Progesterone and modulation of endothelium-dependent responses in canine coronary arteries. Am J Physiol 261 R1022-R1027.
80. CW Jiang, PM Sarrel, DC Lindsay, PA Poole-Wilson and P Collins (1992) Progesterone induces endothelium-independent relaxation of rabbit coronary artery. in vitro. Eur J Pharmacol 211 163-167.
81. JK Williams, EK Honore, SA Washburn and TB Clarkson (1994) Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgous monkeys. J Am Coll Cardiol 24 1757-1761.
82. K Miyagawa, J Rosch, F Stanczyk and K Hermsmeyer (1997) Medroxyprogesterone interferes with ovarian steroid protection against coronary vasospasm. Nat Med 3 324-327.
83. T Simoncini, P Mannella, L Fornari, et al. (2004) Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 145 5745-5756.
84. WS Lee, JA Harder, M Yoshizumi, et al. (1997) Progesterone inhibits arterial smooth muscle cell proliferation. Nat Med 3 1005-1008.
85. S Oparil, RL Levine, SJ Chen, et al. (1997) Sexually dimorphic response of the balloon injured rat carotid artery to hormone treatment. Circulation 95 1301-1307.
86. D Xing, AP Miller, L Novak, et al. (2004) Estradiol and progestins differentially modulate leukocyte infiltration after vascular injury. Circulation 109 234-241.
87. RL Levine, SJ Chen, J Durand, et al. (1996) Medroxyprogesterone attenuates estrogen-mediated inhibition of neointima formation after balloon injury of the rat carotid artery. Circulation 94 2221-2227.
88. JE Sealey, J Itskovitz-Eldor, S Rubattu, et al. (1994) Estradiol- and progesterone-related increases in the renin-aldosterone system: Studies during ovarian stimulation and early pregnancy. J Clin Endocrinol Metab 79 258-264.
89. K Myles and JW Funder (1996) Progesterone binding to mineralocorticoid receptors: in vitro and vivo studies. Am J Physiol 270 E601-E607.
90. LM Braley, AI Menachery, T Yao, et al. (1996) Effect of progesterone on aldosterone secretion in rats. Endocrinology 137 4773-4778.
91. RL Landau, DM Bergenstal, K Lugibihl and ME Kascht (1955) The metabolic effects of progesterone in man. J Clin Endocrinol 15 1194-1215.
92. S Oparil, EN Ehrlich and MD Lindheimer (1975) Effect of progesterone on renal sodium handling in man: Relation to aldosterone excretion and plasma renin activity. Clin Sci Mol Med 49 139-147.
93. MG Brunette and M Leclerc (2002) Renal action of progesterone: effect on calcium reabsorption. Mol Cell Endocrinol 194 183-190.
94. RK Dubey, S Oparil, B Imthurn and EK Jackson (2002) Sex hormones and hypertension. Cardiovasc Res 53 688-708.
95. FP Dunne, DG Barry, JB Ferriss, et al. (1991) Changes in blood pressure during the normal menstrual cycle. Clin Sci 81 515-518. 1991
96. EA Karpanou, GP Vyssoulis, DG Georgoudi, et al. (1993) Ambulatory blood pressure changes in the menstrual cycle of hypertensive women: Significance of plasma renin activity values. Am J Hypertens 6 654-659.
97. AB Chapman, S Zamudio, W Woodmansee, et al. (1997) Systemic and renal hemodynamic changes in the luteal phase of the menstrual cycle mimic early pregnancy. Am J Physiol 273 F777-F782.
98. AP Miller, VB Bittner and S Oparil (2005) Hypertension. N Wenger, P Collins (Eds) Women and Heart Disease 2nd ed. London: Taylor and Francis 441-453.
99. JA Staessen, H Celis and R Fagard (1998) The epidemiology of the association between hypertension and menopause. J Hum Hypertens 12 587-592.
100. JA Staessen, G Ginocchio, L Thijs and R Fagard (1997) Conventional and ambulatory blood pressure and menopause in a prospective population study. J Hum Hypertens 11 507-514.
101. TL Bush, E Barrett-Connor, LD Cowan, et al. (1987) Cardiovascular mortality and noncontraceptive use of estrogen in women: results of the Lipid Research Clinics' program follow-up study. Circulation 75 1102-1109.
102. WB Kannel, MC Hjortland, PM McNamara and T Gordon (1976) Menopause and risk of cardiovascular disease: the Framingham study. Ann Intern Med 85 447-452.
103. E Barrett-Connor, WV Brown, J Turner, et al. (1979) Heart disease risk factors and hormone use in postmenopausal women. JAMA 241 2167-2169.
104. E Barrett-Connor, DI Wingard and MH Criqui (1989) Postmonopausal estrogen use and heart disease risk factors in the 1980s. Rancho Bernardo, Calif., revisited. JAMA 14 2095-2100.
105. G Mercuro, S Zoncu, I Pilia, et al. (1997) Effects of acute administration of transdermal estrogen on postmenopausal women with systemic hypertension. Am J Cardiol 80 652-655.
106. G Mercuro, S Zoncu, D Piano, et al. (1998) Estradiol-17β reduces blood pressure and restore the normal amplitude of the circadian blood pressure rhythm in postmenopausal hypertension. Am J Hypertens 11 909-913.
107. A Butkevich, C Abraham and RA Phillips (2000) Hormone replacement therapy and 24-hour blood pressure profile of postmenopausal women. Am J Hypertens 13 1039-1041.
108. S Wassertheil-Smoller, B Psaty, P Greenland, et al. (2004) Association between cardiovascular outcomes and antihypertensive drug treatment in older women. JAMA 292 2849-2859.
109. Writing Group for the Women's Health Initiative Investigators. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Intitiative randomized controlled trial. JAMA 288 321-333.
110. JE Manson, J Hsai, KC Johnson, et al. (2003) Estrogen plus progestin and the risk of coronary artery disease. The Women's Health Initiative: a randomized trial. N Engl J Med 349 523-534.
111. GL Anderson, M Limacher, AR Assaf, et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291 701-712.
112. GYH Lip, M Beevers, D Churchill and DG Beevers (1994) Hormone replacement therapy and blood pressure in hypertensive women. J Hum Hypertens 8 491-494.
113. S Oparil (2006) Women's health: hormone replacement therapy. H Brunner (Eds) The Year in Hypertension: 2005 Oxford: Clinical Publishing 197-234.
114. AL Hersh, ML Stefanick and RS Stafford (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291 47-53.
115. SR Majumdar, EA Almasi and RS Stafford (2004) Promotion and prescribing of hormone replacement therapy after report of harm after the Women's Health Initiative. JAMA 292 1983-1988.
116. AP Miller, YF Chen, D Xing, et al. (2003) Hormone replacement therapy and inflammation: interactions in cardiovascular disease. Hypertension 42 657-663.
117. SS Girdler, AL Hinderliter, EC Wells, et al. (2004) Transdermal versus oral estrogen therapy in postmenopausal smokers: hemodynamic and endothelial effects. Obstet Gynecol 103 169-180.
118. SM Harman, EA Brinton, M Cedars, et al. (2005) KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 8 3-12.
119. Early versus Late Intervention Trial with Estradiol (ELITE). Home page. Available at: www.usc.edu/schools/medicine/research/centers_programs/aru.elite.html.
120. ML Stefanick, BB Cochrane, J Hsia, et al. (2003) The Women's Health Initiative post-menopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 13 S78-S86.
121. KA Brownley, AL Hinderliter, SG West, et al. (2004) Cardiovascular effects of 6 months of hormone replacement therapy versus placebo: differences associated with years since menopause. Am J Obstet Gynecol 190 1052-1058.
122. Miller AP, Xing D, Feng W, Fintel M, Chen YF, Oparil S. Aged rats lose vasoprotective and anti-inflammatory actions of estrogen in injured arteries. Menopause 2006;December 28 E. pub ahead of print.
123. LS Phillips and RD Langer (2005) Postmenopausal hormone therapy: critical reappraisal and a unified hypothesis. Fertil Steril 83 558-566.
124. E Barrett-Connor, L Mosca, P Collins, et al. (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355 125-137.
125. MG Crane, JJ Harris and W Winsor (1971) Hypertension, oral contraceptive agents and conjugated estrogens. Ann Intern Med 74 13-21.
126. RL Prentice (1988) On the ability of blood pressure effects to explain the relation between oral contraceptives and cardiovascular disease. Am J Epidemiol 127 213-219.
127. W Dong, HM Colhoun and NR Poulter (1997) Blood pressure in women using oral contraceptives: results from the Health Survey for England 1994. J Hypertens 15 1063-1068.
128. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. (1995) A multinational case-control study of cardiovascular disease and steroid hormone contraceptives: description and validation of methods. J Clin Epidemiol 48 1513-1547.
129. JN Lubianca, CS Faccin and FD Fuchs (2003) Oral contraceptives: a risk factor for uncontrolled blood pressure among hypertensive women. Contraception 67 19-24.
130. NK Hollenberg, GF Williams, B Burger, et al. (1976) Renal blood flow and its response to angiotensin II. An interaction between oral contraceptive agents, sodium intake and the renin-angiotensin system in healthy young women. Clin Res 38 35-40.
131. SG Rockson, RA Stone, JC Gunnells, et al. (1975) Plasma dopamine β-hydroxylase activity in oral contraceptive hypertension. Circulation 51 916-923.
132. IF Godsland and D Crook (1994) Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk. Am J Obstet Gynecol 170 1528-1536.
133. WAW Walters and YL Lim (1970) Haemodynamic changes in women taking oral contraceptives. J Obstet Gynaecol Br Commonw 77 1007-1012.
134. CW Burke (1969) Biologically active cortisol in plasma of oestrogen-treated adrenal subjects. BMJ 2 798-800.
135. WD Hall, MB Douglas, B Blumenstein and RA Hatcher (1980) Blood pressure and oral progestational agents. A prospective study of 199 black women. Am J Obstet Gynecol 136 344-348.
136. ESB Wilson, J Cruikshank, M McMaster and RJ Weir (1984) A prospective controlled study of the effect on blood pressure of contraceptive preparations containing different types and dosages of progestagen. Br J Obstet Gynaecol 91 1254-1260.
137. Royal College of General Practitioners. (1974) Oral Contraceptives and Health New York: Pittman 34-42.
138. KT Khaw and WS Peart (1985) Blood pressure and contraceptive use. BMJ 285 403-407.
139. WN Spellacy and SA Birk (1972) The effect of intrauterine devices, oral contraceptives, estrogens, and progestogens and blood pressure. Am J Obstet Gynecol 112 912-919.
140. SF Hussain (2004) Progestogen-only pills and high blood pressure: is there an association? A literature review. Contraception 69 89-97.
141. RJ Weir, E Briggs, A Mack, et al. (1974) Blood pressure in women taking oral contraceptives. BMJ 1 533-535.
142. O Meirik, TM Farley and I Sivin (2001) Safety and efficacy of levonorgestrel implant, intrauterine device, and sterilization. Obstet Gynecol 97 539-547.
143. HB Croxatto, J Urbancsek, R Massai, et al. (1999) A multicentre efficacy and safety study of the single contraceptive implant Implanon. Implanon Study Group. Hum Reprod 14 976-981.
144. I Sivin (2003) Risks and benefits, advantages and disadvantages of levonorgestrel-releasing contraceptive implants. Drug Saf 26 303-335.
145. R Sitruk-Ware (2004) Pharmacological profile of progestins. Maturitas 47 277-283.
146. W Oelkers, V Berger, A Bolik, V Bahr, B Hazard, S Beier, et al. (1991) Dihydrospirorenone—a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion and the renin-aldosterone system in normal women. J Clin Endocrinol Metab 73 837-842.
147. W Elger, S Beier, K Pollow, et al. (2003) Conception and pharmacodynamic profile of drospirenone. Steroids 68 891-905.
148. W Oelkers (2004) Drospirenone, a progestogen with antimineralocorticoid properties: a short review. Mol Cell Endocrinol 217 255-261.
149. DA Sica (2006) Drospirenone: an antihypertensive in waiting. Hypertension 48 205-206.
150. W Oelkers, JM Foidart, N Dombrovicz, et al. (1995) Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab 80 1816-1821.
151. RA Preston, A Alonso, D Panzitta, et al. (2002) Additive effect of drospirenone/17|3-estradiol in hypertensive postmenopausal women receiving enalapril. Am J Hypertens 15 816-822.
152. RA Preston, WB White, B Pitt, et al. (2005) Effects of drospirenone/17|3-estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 18 797-804.
153. WB White, B Pitt, RA Preston and V Hanes (2005) Antihypertensive effects of drospirenone with 17|3-estradiol, a novel hormonal treatment in postmenopausal women with stage 1 hypertension. Circulation 112 1979-1984.
154. WB White, V Hanes, V Chauhan and B Pitt (2006) Effects of a new hormone therapy, drospirenone and 17|3-estradiol, in postmenopausal women with hypertension. Hypertension 48 246-253.
155. C Rosendorff (2005) Progestin and potassium. Am J Hypertens 18 741-743.
156. DF Archer, IH Thorneycroft, M Foegh, et al. (2005) Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 12 716-727.